Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
TVTravere Therapeutics, Inc. logo

Travere Therapeutics, Inc. (TVTX)

NASDAQ Global Market · Currency in USD
$50.08 ▼ -2.35 (-4.48%)
At close: Oct 23, 4:00 PM ET. Market closed.
$50.50 ▲ +0.42 (+0.84%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$52.43
Open
$52.00
Day's Range
$49.77 – $52.00
52 Week Range
$22.59 – $68.73
Volume
2,314,346
Avg. Volume
1,731,354
Market Cap
$4.72B
Beta (5Y Monthly)
1.14
PE Ratio (TTM)
--
EPS (TTM)
-$0.46
Earnings Date
Oct 29, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$76.00

Profile: Travere Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
497
CEO
Eric Dube

Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression.

Earnings

Next report: Thu, Oct 29, 2026
EPS estimate -$0.04 · Revenue est. $198.32M
DateEst.Actual
Aug 4, 2026-$0.13-$0.37Miss
May 4, 2026-$0.30-$0.39Miss
Feb 19, 2026$0.03$0.03Beat
Oct 30, 2025-$0.31$0.28Beat
Aug 6, 2025-$0.28-$0.14Beat
May 1, 2025-$0.55-$0.47Beat

Analyst view

Consensus price target
$76.00 ▲ +51.8%
Range $67.00 – $89.00
Rating: Buy
Buy 83% · Hold 17% · Sell -0%

Get free alerts on TVTX and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.